… This poor representation in research results in an incomplete picture of the disease and disparities in care. The … areas of action: 1) identifying barriers and solutions to research participation; 2) funding inclusive research … workforce committed to health equity; and 4) supporting a more holistic understanding of PD. While …

… other studies. Data and analysis from AMP PD made available to qualified researchers to accelerate discovery and … Medicines Partnership model. MJFF and five life sciences companies are contributing a combined total of $12 million … pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement …

… Read about how the 13-year journey to visualize alpha-synuclein — “the Parkinson’s protein” — in the living brain has resulted in a major step toward an imaging tool for PD. Plus, learning about … PPMI, historic legislation in Congress and updates from our community. …

… disease of the part of the brain that controls motor function. Brain-derived neurotrophic factors promote … bioavailable after oral administration in man. AMPAKINE® compounds stimulate production of such neurotrophic factors … are reduced in PD and are neuroprotective in models of PD. However, brain growth factors are not orally bioavailable …

… MJFF CEO Todd Sherer, PhD, and Chief Science Officer Brian Fiske, … understand Parkinson’s without interacting with the patient community and encouraging them to participate in clinical … MJFF established the J. William Langston Award in 2006 to show our appreciation to our hard-working advisors. Langston …

… Today, MJFF CEO Todd Sherer, PhD, published an op-ed in The Hill urging lawmakers to create a national plan to support scientific breakthroughs for Parkinson's disease … Parkinson's, will explode as diagnoses rise, and the NIH budget of $34.1 billion is simply not enough given the …